Raloxifene increases the risk of gastroesophageal reflux disease, Barrett's esophagus, and esophageal stricture in postmenopausal women with osteoporosis.
Barrett's esophagus
esophageal stricture
gastroesophageal reflux disease
postmenopausal women
raloxifene
Journal
Neurogastroenterology and motility
ISSN: 1365-2982
Titre abrégé: Neurogastroenterol Motil
Pays: England
ID NLM: 9432572
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
revised:
12
09
2023
received:
16
08
2023
accepted:
27
09
2023
medline:
1
12
2023
pubmed:
9
10
2023
entrez:
9
10
2023
Statut:
ppublish
Résumé
Estrogen-based therapies may increase the risk of gastroesophageal reflux (GERD) and its complications. We aimed to determine the effect of raloxifene on the development of GERD, Barrett's esophagus, and esophageal stricture in postmenopausal women with osteoporosis. This was a population-based, propensity-matched cohort study using the TriNetX platform. Patients 50 years and older with a diagnosis of "menopause" and "osteoporosis" were included in this study. Odds ratios (OR) and 95% confidence intervals (CI) were calculated for new GERD, esophageal stricture and Barrett's esophagus after raloxifene exposure. The control cohort consisted of patients who did not start any hormonal replacement therapy. We conducted a multivariable logistic regression analysis to evaluate the effect of confounding variables and also addressed common confounding medications with 1:1 propensity score-matching. Internal validity was confirmed by comparing to negative controls (lisinopril, atorvastatin) and positive controls (metformin, ibuprofen, aspirin). Five thousand four hundred and seventy two postmenopausal women with osteoporosis were on raloxifene of which 1908 (34.86%) developed GERD, compared to 296,067 postmenopausal who were not on raloxifene of which 90,643 (30.62%) developed GERD (OR 1.2; 95% CI 1.10-1.31, p < 0.0001). This persisted after adjusting for common medications known to affect GERD. Raloxifene was identified as a risk factor for GERD in a multivariate analysis, controlling for factors including age, obesity, smoking, and alcohol use (OR 1.51, 95% Wald CI 1.47-1.53). Raloxifene was associated with esophageal stricture (OR 1.60; 95% Wald CI 1.51-1.69) and Barrett's esophagus (OR 1.50; 95% Wald CI 1.37-1.63) in multivariate analysis. These associations persisted using sensitivity analyses. Raloxifene increases the risk of GERD, esophageal stricture and Barrett's esophagus in postmenopausal women with osteoporosis. Further studies are needed to confirm our findings.
Sections du résumé
BACKGROUND AND AIMS
OBJECTIVE
Estrogen-based therapies may increase the risk of gastroesophageal reflux (GERD) and its complications. We aimed to determine the effect of raloxifene on the development of GERD, Barrett's esophagus, and esophageal stricture in postmenopausal women with osteoporosis.
METHODS
METHODS
This was a population-based, propensity-matched cohort study using the TriNetX platform. Patients 50 years and older with a diagnosis of "menopause" and "osteoporosis" were included in this study. Odds ratios (OR) and 95% confidence intervals (CI) were calculated for new GERD, esophageal stricture and Barrett's esophagus after raloxifene exposure. The control cohort consisted of patients who did not start any hormonal replacement therapy. We conducted a multivariable logistic regression analysis to evaluate the effect of confounding variables and also addressed common confounding medications with 1:1 propensity score-matching. Internal validity was confirmed by comparing to negative controls (lisinopril, atorvastatin) and positive controls (metformin, ibuprofen, aspirin).
RESULTS
RESULTS
Five thousand four hundred and seventy two postmenopausal women with osteoporosis were on raloxifene of which 1908 (34.86%) developed GERD, compared to 296,067 postmenopausal who were not on raloxifene of which 90,643 (30.62%) developed GERD (OR 1.2; 95% CI 1.10-1.31, p < 0.0001). This persisted after adjusting for common medications known to affect GERD. Raloxifene was identified as a risk factor for GERD in a multivariate analysis, controlling for factors including age, obesity, smoking, and alcohol use (OR 1.51, 95% Wald CI 1.47-1.53). Raloxifene was associated with esophageal stricture (OR 1.60; 95% Wald CI 1.51-1.69) and Barrett's esophagus (OR 1.50; 95% Wald CI 1.37-1.63) in multivariate analysis. These associations persisted using sensitivity analyses.
CONCLUSION
CONCLUSIONS
Raloxifene increases the risk of GERD, esophageal stricture and Barrett's esophagus in postmenopausal women with osteoporosis. Further studies are needed to confirm our findings.
Substances chimiques
Raloxifene Hydrochloride
4F86W47BR6
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14689Informations de copyright
© 2023 John Wiley & Sons Ltd.
Références
Fass R, Boeckxstaens GE, El-Serag H, Rosen R, Sifrim D, Vaezi MF. Gastro-oesophageal reflux disease. Nat Rev Dis Primers. 2021;7(1):55. doi:10.1038/s41572-021-00287-w
Sandler RS, Everhart JE, Donowitz M, et al. The burden of selected digestive diseases in the United States. Gastroenterology. 2002;122(5):1500-1511. doi:10.1053/gast.2002.32978
Nilsson M, Johnsen R, Ye W, Hveem K, Lagergren J. Obesity and estrogen as risk factors for gastroesophageal reflux symptoms. Jama. 2003;290(1):66-72. doi:10.1001/jama.290.1.66
Lindblad M, García Rodríguez LA, Chandanos E, Lagergren J. Hormone replacement therapy and risks of oesophageal and gastric adenocarcinomas. Br J Cancer. 2006;94(1):136-141. doi:10.1038/sj.bjc.6602906
Saleh S, Trujillo S, Ghoneim S, Thomas C, Fass R. Effect of hormonal replacement therapy on gastroesophageal reflux disease and its complications in postmenopausal women. Clinical Gastroenterol Hepatol. 2023;21(2):549-551.e3. doi:10.1016/j.cgh.2022.01.058
Close H, Mason JM, Wilson D, Hungin AP. Hormone replacement therapy is associated with gastro-oesophageal reflux disease: a retrospective cohort study. BMC Gastroenterol. 2012;12:56. doi:10.1186/1471-230x-12-56
Menon S, Nightingale P, Trudgill N. Is hormone replacement therapy in post-menopausal women associated with a reduced risk of oesophageal cancer? United Euro Gastroenterol J. 2014;2(5):374-382. doi:10.1177/2050640614543736
Jacobson BC, Moy B, Colditz GA, Fuchs CS. Postmenopausal hormone use and symptoms of gastroesophageal reflux. Arch Intern Med. 2008;168(16):1798-1804. doi:10.1001/archinte.168.16.1798
Nordenstedt H, Zheng Z, Cameron AJ, Ye W, Pedersen NL, Lagergren J. Postmenopausal hormone therapy as a risk factor for gastroesophageal reflux symptoms among female twins. Gastroenterology. 2008;134(4):921-928. doi:10.1053/j.gastro.2008.01.009
Kang A, Khokale R, Awolumate OJ, Fayyaz H, Cancarevic I. Is estrogen a curse or a blessing in disguise? Role of estrogen in gastroesophageal reflux disease. Cureus. 2020;12(10):e11180. doi:10.7759/cureus.11180
Best PJ, Berger PB, Miller VM, Lerman A. The effect of estrogen replacement therapy on plasma nitric oxide and endothelin-1 levels in postmenopausal women. Annals of Internal Medicine. 1998;128(4):285-288. doi:10.7326/0003-4819-128-4-199802150-00006
Chen C, Gong X, Yang X, et al. The roles of estrogen and estrogen receptors in gastrointestinal disease. Oncol Lett. 2019;18(6):5673-5680. doi:10.3892/ol.2019.10983
Saleh S, Liu BD, Trujillo S, Thomas C, Fass R. The effect of combined oral contraceptives and Nexplanon on gastroesophageal reflux disease in premenopausal women: a nationwide database analysis. Neurogastroenterol & Motil. 2023;n/a(n/a):e14542. doi:10.1111/nmo.14542
An KC. Selective Estrogen Receptor Modulators. Asian Spine J. 2016;10(4):787-791. doi:10.4184/asj.2016.10.4.787
Quintanilla Rodriguez BS, Correa R. Raloxifene. StatPearls Publishing; 2022.
Farrar MC, Jacobs TF. Tamoxifen. StatPearls Publishing; 2022.
Ali RAR, Egan LJ. Gastroesophageal reflux disease in pregnancy. Best Practice & Research Clinical. Gastroenterology. 2007;21(5):793-806. doi:10.1016/j.bpg.2007.05.006
von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370(9596):1453-1457. doi:10.1016/s0140-6736(07)61602-x
TriNetX L. TriNetX.com. Accessed February 13, 2023. Trinetx.com
Haukoos JS, Lewis RJ. The propensity score. Jama. 2015;314(15):1637-1638. doi:10.1001/jama.2015.13480
VanderWeele TJ, Ding P. Sensitivity analysis in observational research: introducing the E-value. Annals of Internal Medicine. 2017;167(4):268-274. doi:10.7326/m16-2607
Barrett-Connor E, Mosca L, Collins P, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med. 2006;355(2):125-137. doi:10.1056/NEJMoa062462
Hirsch DP, Holloway RH, Tytgat GN, Boeckxstaens GE. Involvement of nitric oxide in human transient lower esophageal sphincter relaxations and esophageal primary peristalsis. Gastroenterology. 1998;115(6):1374-1380. doi:10.1016/s0016-5085(98)70015-0